TREPROSTINIL TEVA 5 MGML
Country: Israel
Language: English
Source: Ministry of Health
Public Assessment Report
(PAR)
29-07-2021
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
TREPROSTINIL AS SODIUM
Available from:
ABIC MARKETING LTD, ISRAEL
ATC code:
B01AC21
Pharmaceutical form:
SOLUTION FOR INFUSION
Composition:
TREPROSTINIL AS SODIUM 5 MG/ML
Administration route:
S.C, I.V
Prescription type:
Not required
Manufactured by:
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
Therapeutic area:
TREPROSTINIL
Therapeutic indications:
Treprostinil Teva is indicated for the treatment of:- Primary pulmonary arterial hypertension - Pulmonary arterial hypertension associated with connective tissue disorders.- Pulmonary hypertension associated with congenital systemic to pulmonary shunts.
Authorization date:
2020-11-29
